MED vs NUS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

MED

39.2
AI Score
VS
NUS Wins

NUS

43.0
AI Score

Investment Advisor Scores

MED

39score
Recommendation
SELL

NUS

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED NUS Winner
Revenue 224.48M 951.73M NUS
Net Income -22.73M -248.70M MED
Gross Margin 69.1% 66.7% MED
Net Margin -10.1% -26.1% MED
Operating Income -26.98M -50.21M MED
ROE -12.6% -45.4% MED
ROA -9.5% -22.9% MED
Total Assets 239.76M 1.09B NUS
Cash 58.37M 164.90M NUS
Current Ratio 4.82 2.04 MED
Free Cash Flow 2.76M -32.12M MED

Relative Price Performance (Last 90 Days)

MED 1M: +8.5% · 3M: +12.4% NUS 1M: -21.5% · 3M: -16.5%

Current Technical Phase

MED

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 57

RSI (14): 56.9 · Price: $12.86

NUS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 36

RSI (14): 36.2 · Price: $4.01

Fundamentals Snapshot

Metric MED NUS
Market Cap — —
Forward P/E -321.5 3.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% -0.1%
Gross Margin 0.7% 0.7%
Operating Margin -0.1% 0.0%
EPS -3.70 -4.86
Dividend Yield — 0.06%

Frequently Asked Questions

Based on our detailed analysis, NUS is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.